Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
Posted:
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
From detecting TB, cancer, and heart attacks to diagnosing patients with strokes and diabetes, Artificial Intelligence (AI) is redefining the healthcare system across the world. Currently, more than 90% of hospitals and healthcare systems have implemented an AI or automation strategy,…